MediciNova, Inc. Announces Publication of MN-221 Clinical Results in Journal of Asthma
11/13/2012 9:01:02 AM
SAN DIEGO, Nov. 12, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced the publication of positive Phase 2 clinical results in two asthma studies in the Journal of Asthma. The publication is entitled, "Evaluation of Bedoradrine Sulfate (MN-221), a Novel, Highly Selective Beta(2)-Adrenergic Receptor Agonist for the Treatment of Asthma via Intravenous Infusion" and is available online.